MXPA06001110A - Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer. - Google Patents

Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer.

Info

Publication number
MXPA06001110A
MXPA06001110A MXPA06001110A MXPA06001110A MXPA06001110A MX PA06001110 A MXPA06001110 A MX PA06001110A MX PA06001110 A MXPA06001110 A MX PA06001110A MX PA06001110 A MXPA06001110 A MX PA06001110A MX PA06001110 A MXPA06001110 A MX PA06001110A
Authority
MX
Mexico
Prior art keywords
kinase inhibitor
cancer
inhibition
treatment
combination
Prior art date
Application number
MXPA06001110A
Other languages
English (en)
Inventor
Lee Martin Greenberger
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA06001110A publication Critical patent/MXPA06001110A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invencion describe combinaciones que comprenden un agente citotoxico y un inhibidor de cinasa EGFR y metodo para tratar o inhibir cancer en un mamifero que necesite del mismo el cual comprende administrar al mamifero una cantidad efectiva de un agente citotoxico y un inhibidor de cinasa EGFR.
MXPA06001110A 2003-08-01 2004-07-28 Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer. MXPA06001110A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49213203P 2003-08-01 2003-08-01
PCT/US2004/024478 WO2005018677A2 (en) 2003-08-01 2004-07-28 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer

Publications (1)

Publication Number Publication Date
MXPA06001110A true MXPA06001110A (es) 2006-04-11

Family

ID=34215843

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06001110A MXPA06001110A (es) 2003-08-01 2004-07-28 Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer.

Country Status (19)

Country Link
US (1) US20050026933A1 (es)
EP (1) EP1648516A2 (es)
JP (1) JP2007501238A (es)
KR (1) KR20060054412A (es)
CN (1) CN1832757A (es)
AR (1) AR045179A1 (es)
AU (1) AU2004266572A1 (es)
BR (1) BRPI0413255A (es)
CA (1) CA2533126A1 (es)
CO (1) CO5640151A2 (es)
CR (1) CR8181A (es)
EC (1) ECSP066341A (es)
IL (1) IL173081A0 (es)
MX (1) MXPA06001110A (es)
NO (1) NO20060398L (es)
RU (1) RU2006106267A (es)
TW (1) TW200515910A (es)
WO (1) WO2005018677A2 (es)
ZA (1) ZA200600915B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009473A (es) * 2002-03-29 2005-02-03 Exxonmobil Chem Patents Inc Oligomerizacion de olefinas.
MXPA04009472A (es) * 2002-03-29 2005-02-03 Exxonmobil Chem Patents Inc Preparacion de hidrocarburos alquilaromaticos y alquilaril sulfonatos.
KR101289774B1 (ko) 2004-03-31 2013-08-07 다나-파버 캔서 인스티튜트 인크. 표피성장인자 수용체를 표적으로 하는 치료에 대한 암의반응성을 결정하는 방법
RU2006146612A (ru) * 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr)
RU2006146623A (ru) * 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение оксалиплатином и ингибитором рецептора эпидермального фактора роста (egfr)
PL1848414T3 (pl) 2005-02-03 2011-10-31 Wyeth Llc Sposób leczenia nowotworu opornego na gefitinib
EP2594631A1 (en) 2005-04-05 2013-05-22 Cellpoint Diagnostics Devices and method for detecting circulating tumor cells and other particles
MX2007012662A (es) * 2005-04-14 2008-04-04 Wyeth Corp Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib.
RU2447889C2 (ru) * 2005-07-18 2012-04-20 Бипар Сайенсиз, Инк. Способ лечения рака (варианты)
EP1906977B1 (en) * 2005-07-21 2012-02-22 Nuvo Research AG Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
WO2007139930A2 (en) * 2006-05-26 2007-12-06 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
AU2007354301A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with PARP inhibitors
WO2008030883A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
AU2007292306A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
JP2010503696A (ja) * 2006-09-13 2010-02-04 ヌベロ， インコーポレイテッド 癌を処置するための方法
DE102007024470A1 (de) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2217227B1 (en) * 2007-11-12 2013-08-21 BiPar Sciences, Inc. Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
AU2008321382A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
RU2010128107A (ru) * 2007-12-07 2012-01-20 Байпар Сайенсиз, Инк. (Us) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
CN102202667A (zh) 2008-08-04 2011-09-28 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
MY156789A (en) * 2008-09-05 2016-03-31 Celgene Avilomics Res Inc Algorithm for designing irreversible inhibitors
MX356593B (es) 2009-04-06 2018-06-05 Wyeth Llc Régimen de tratamiento que utiliza neratinib para cáncer de mama.
SG179172A1 (en) 2009-09-16 2012-04-27 Avila Therapeutics Inc Protein kinase conjugates and inhibitors
WO2011056741A2 (en) 2009-11-09 2011-05-12 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
SG181965A1 (en) 2009-12-30 2012-08-30 Avila Therapeutics Inc Ligand-directed covalent modification of protein
ES2813875T3 (es) 2014-01-01 2021-03-25 Medivation Tech Llc Compuestos y procedimientos de uso
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220229072A1 (en) 2019-06-04 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6384051B1 (en) * 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
AR037438A1 (es) * 2001-11-27 2004-11-10 Wyeth Corp 3-cianoquinolinas como inhibidores de egf-r y her2 quinasas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos

Also Published As

Publication number Publication date
BRPI0413255A (pt) 2006-10-03
CA2533126A1 (en) 2005-03-03
IL173081A0 (en) 2006-06-11
TW200515910A (en) 2005-05-16
CN1832757A (zh) 2006-09-13
RU2006106267A (ru) 2006-07-27
JP2007501238A (ja) 2007-01-25
ECSP066341A (es) 2006-08-30
AU2004266572A1 (en) 2005-03-03
WO2005018677A3 (en) 2006-05-26
AR045179A1 (es) 2005-10-19
EP1648516A2 (en) 2006-04-26
WO2005018677A2 (en) 2005-03-03
CO5640151A2 (es) 2006-05-31
US20050026933A1 (en) 2005-02-03
KR20060054412A (ko) 2006-05-22
CR8181A (es) 2006-07-14
NO20060398L (no) 2006-02-28
ZA200600915B (en) 2007-12-27

Similar Documents

Publication Publication Date Title
MXPA06001110A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer.
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
SG148202A1 (en) Quinazolinone compounds as anticancer agents
TN2010000209A1 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
WO2004043374A3 (en) Methods and compositions for treating cancer using proteasome inhibitors
TW200718421A (en) Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
EP1551812A4 (en) MITOTIC KINESINE HEMMER
EP1463733A4 (en) INHIBITORS OF MITOTIC KINESIN
EP1481077A4 (en) MITOTIC KINESINE HEMMER
PT1682126E (pt) Benzazois substituídos e sua utilização como inibidores da quinase raf
EP1492487A4 (en) INHIBITORS OF MITOTIC KINESIN
TN2010000208A1 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
EP1515949A4 (en) INHIBITORS OF MITOTIC KINESIN
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2003039545A3 (en) Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
MX2010004967A (es) Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso.
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
MXPA05011213A (es) Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia.
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
WO2007110705A3 (en) Macrolide as inhibitors of mhc class ii
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal